NICE Draft Negs Tarceva, Alimta For Treatment Of NSCLC
This article was originally published in The Pink Sheet Daily
Executive Summary
Neither Roche's erlotinib or Lilly's pemetrexed represent "good use of scarce" resources, NICE says in preliminary reports.